索他洛尔与胺碘酮治疗快速型心律失常的疗效观察

Efficacy Observation of Sotalol and Amiodarone on Treating Tachyarrhythmia

目的:比较索他洛尔与胺碘酮治疗快速型心律失常患者的效果。方法:选取2020年1月-2021年1月潜江市人民医院收治的80例快速型心律失常患者,随机数表法分为对照组和试验组,各40例。对照组给予索他洛尔,试验组给予胺碘酮。比较两组临床疗效、心电图(PR间期、QRS间期、QT间期)、实验室指标[一氧化氮(NO)、内皮素-1(ET-1)、血栓素B2(TXB2)、6-同前列腺素F-1α(6-keto-PGF-1α)]及不良反应。结果:试验组总有效率高于对照组,差异具有统计学意义(χ2=4.501,P=0.034)。治疗后,两组PR间期、QRS间期均升高,QT间期降低,差异具有统计学意义(P<0.05);试验组PR间期、QRS间期均高于对照组,QT间期低于对照组,差异具有统计学意义(P<0.05)。治疗后,两组NO、6-keto-PGF-1α水平均升高,ET-1、TXB2水平均降低,差异具有统计学意义(P<0.05);相较于对照组,试验组治疗后NO、6-keto-PGF-1α水平均较高,ET-1、TXB2水平均较低,差异具有统计学意义(χ2=1.127,P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:胺碘酮治疗快速型心律失常患者比索他洛尔具有更高的临床疗效,在纠正心电图异常、改善实验室指标水平方面效果更佳,安全性好。

Objective:To compare the effects of sotalol and amiodarone in treatment of patients with tachyarrhythmias.Methods:A total of 80 patients with tachyarrhythmias who were treated in Qianjiang People's Hospital from January 2020 to January 2021 were selected,and they were divided into control group and experimental group by random number table method,with 40 cases in each group.The control group was treated with sotalol,and the experimental group was treated with amiodarone.The clinical efficacy,electrocardiogram(PR interval,QRS interval,QT interval),laboratory index[nitric oxide(NO),endothelin-1(ET-1),thromboxane B2(TXB2),6-keto-prostaglandin F-1α(6-keto-PGF-1α)]and adverse reactions were compared between the two groups.Results:The total effective rate in the experimental group was higher than that in the control group,and the difference was statistically significant(χ2=4.501,P=0.034).After treatment,the PR interval and QRS interval of the two groups were increased,and the QT interval was decreased,and the difference was statistically significant(P<0.05).The PR interval and QRS interval of the experimental group were higher than those of the control group,and the QT interval lower than the control group,the difference was statistically significant(P<0.05).After treatment,the levels of NO and 6-keto-PGF-1αin the two groups were increased,and the levels of ET-1 and TXB2 were decreased,and the difference was statistically significant(P<0.05).Compared with the control group,the levels of NO and 6-keto-PGF-1αin the experimental group were higher,while the levels of ET-1 and TXB2 in the experimental group were lower after treatment,and the difference was statistically significant(χ2=1.127,P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:For patients with tachyarrhythmia,amiodarone has a higher clinical efficacy than sotalol,and it is more effective in correcting ECG abnormalities and improving laboratory index levels,with good safety.